Literature DB >> 8645589

Waning sexual function--the most important disease-specific distress for patients with prostate cancer.

A R Helgason1, J Adolfsson, P Dickman, M Fredrikson, S Arver, G Steineck.   

Abstract

The objective was to investigate how prostate cancer and its treatment affects sexual, urinary and bowel functions and to what extent eventual complications cause distress. A questionnaire was sent to 431 men aged 50-80 years with prostate cancer diagnosed in 1992 in the Stockholm area (Sweden) and 435 randomly selected men with a similar age distribution. Sexual function, as compared with their youth, was diminished in a majority of all men. The prostate cancer patients were, however, more likely to report low frequency and/or intensity in all aspects of sexual function. A majority of the men were distressed by a waning sexual capacity. The proportion of men with prostate cancer who were severely distressed owing to a decline in sexual function was larger than in the reference group. The willingness to trade off an intact sexual function for long-term survival varied considerably among the men in the reference group. Urinary and bowel symptoms were less common than a waning sexual function in both groups, and few appeared to be severely distressed by urinary or bowel symptoms. A decline in sexual functions was the most common cause of disease-specific distress in men with prostate cancer.

Entities:  

Mesh:

Year:  1996        PMID: 8645589      PMCID: PMC2074472          DOI: 10.1038/bjc.1996.268

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  [Sexual activity after pelvic irradiation for cancer of the prostate. Evaluation by questionnaire].

Authors:  C Berger; F P Rocher; Y Zhu; P Romestaing; L Ayzac; J P Gérard
Journal:  J Urol (Paris)       Date:  1993

2.  Quality of life after radical retropubic prostatectomy for carcinoma of the prostate.

Authors:  K V Pedersen; P Carlsson; M Rahmquist; E Varenhorst
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

3.  Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993).

Authors:  F J Fowler; M J Barry; G Lu-Yao; A Roman; J Wasson; J E Wennberg
Journal:  Urology       Date:  1993-12       Impact factor: 2.649

4.  Quality of life 12 months after radical prostatectomy.

Authors:  K G Braslis; C Santa-Cruz; A L Brickman; M S Soloway
Journal:  Br J Urol       Date:  1995-01

5.  Sex or survival: trade-offs between quality and quantity of life.

Authors:  P A Singer; E S Tasch; C Stocking; S Rubin; M Siegler; R Weichselbaum
Journal:  J Clin Oncol       Date:  1991-02       Impact factor: 44.544

6.  Decreased sexual capacity after external radiation therapy for prostate cancer impairs quality of life.

Authors:  A R Helgason; M Fredrikson; J Adolfsson; G Steineck
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-04-30       Impact factor: 7.038

7.  Tumor control in definitive irradiation of localized carcinoma of the prostate.

Authors:  A A Perez; M V Pilepich; F Zivnuska
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-04       Impact factor: 7.038

8.  Sexual rehabilitation after treatment for prostate cancer.

Authors:  L R Schover
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

9.  Quality-of-life outcomes in men treated for localized prostate cancer.

Authors:  M S Litwin; R D Hays; A Fink; P A Ganz; B Leake; G E Leach; R H Brook
Journal:  JAMA       Date:  1995-01-11       Impact factor: 56.272

10.  Sequelae of radical prostatectomy.

Authors:  M Jønler; E M Messing; P R Rhodes; R C Bruskewitz
Journal:  Br J Urol       Date:  1994-09
  10 in total
  26 in total

Review 1.  Sexual function and rehabilitation after radiation therapy for prostate cancer: a review.

Authors:  David-Dan Nguyen; Alejandro Berlin; Andrew G Matthew; Nathan Perlis; Dean S Elterman
Journal:  Int J Impot Res       Date:  2021-01-06       Impact factor: 2.896

2.  Athermal early retrograde release of the neurovascular bundle during nerve-sparing robotic-assisted laparoscopic radical prostatectomy.

Authors:  Geoffrey Coughlin; Pankaj P Dangle; Kenneth J Palmer; Srinivas Samevedi; Vipul R Patel
Journal:  J Robot Surg       Date:  2009-02-03

Review 3.  A review of quality-of-life evaluations in prostate cancer.

Authors:  S D Sommers; S D Ramsey
Journal:  Pharmacoeconomics       Date:  1999-08       Impact factor: 4.981

4.  The effect of erectile dysfunction on quality of life following treatment for localized prostate cancer.

Authors:  D F Penson
Journal:  Rev Urol       Date:  2001

Review 5.  Eroticization as a factor influencing erectile dysfunction treatment effectiveness.

Authors:  K C Kukula; R A Jackowich; R J Wassersug
Journal:  Int J Impot Res       Date:  2013-07-04       Impact factor: 2.896

Review 6.  Prostate cancer and health-related quality of life: a review of the literature.

Authors:  David T Eton; Stephen J Lepore
Journal:  Psychooncology       Date:  2002 Jul-Aug       Impact factor: 3.894

7.  Loss of masculine identity, marital affection, and sexual bother in men with localized prostate cancer.

Authors:  Talia Zaider; Sharon Manne; Christian Nelson; John Mulhall; David Kissane
Journal:  J Sex Med       Date:  2012-09-18       Impact factor: 3.802

8.  Multilevel modeling in psychosomatic medicine research.

Authors:  Nicholas D Myers; Ahnalee M Brincks; Allison J Ames; Guillermo J Prado; Frank J Penedo; Catherine Benedict
Journal:  Psychosom Med       Date:  2012-10-29       Impact factor: 4.312

9.  Preferences of husbands and wives for outcomes of prostate cancer screening and treatment.

Authors:  Robert J Volk; Scott B Cantor; Alvah R Cass; Stephen J Spann; Susan C Weller; Murray D Krahn
Journal:  J Gen Intern Med       Date:  2004-04       Impact factor: 5.128

10.  The unrecognised cost of cancer patients' unrelieved symptoms:a nationwide follow-up of their surviving partners.

Authors:  U Valdimarsdóttir; A R Helgason; C-J Fürst; J Adolfsson; G Steineck
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.